Plus Therapeutics (PSTV) appointed Michael Rosol as Chief Development Officer. Rosol will lead the company’s clinical, pre-clinical, and biomarker development activities. Rosol most recently served as Chief Medical Officer and Senior Vice President at Navidea Biopharmaceuticals. Prior to his most recent role, Rosol worked at Novartis Pharmaceuticals.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.